NR 603 Week 1 Discussion_Complexity and Clinical Decision-Making Case

T4, A1c, BMP/eGFR, urine albumin/creatinine, and a lipid panel). Medication choice must consider affordability, dosing simplicity, and monitoring burden. The ADA's Standards of Care emphasize individualized diabetes management that accounts for comorbidities, cardiovascular risk, and access/cost barriers (American Diabetes Association, 2025). LEP requires process decisions (interpreter use, bilingual materials, teach-back) to reduce errors and improve adherence (Woods et al., 2022). Finally, prioritization matters: while hypothyroidism should be confirmed and treated, immediate risk reduction may require earlier optimization of blood pressure and glycemic control due to their near-term cardiovascular implications. Guideline-informed management plan (primary and secondary diagnoses). Primary diagnosis—Hypothyroidism: The AACE/ATA clinical practice guideline recommends confirming hypothyroidism using an elevated TSH with an appropriate free T4 pattern before initiating therapy, followed by levothyroxine titration with repeat TSH testing about every 6–8 weeks after initiation or dose changes (Garber et al., 2012). Maria should be counseled to take levothyroxine on an empty stomach and separate it from calcium/iron supplements to support absorption and reduce treatment failure. Secondary diagnosis—T2DM: The ADA Standards of Care provide annually updated recommendations emphasizing individualized A1c targets, assessment of kidney and cardiovascular risk, and selection of therapies aligned with comorbidities and patient access (American Diabetes Association, 2025). For Maria, obtain A1c, eGFR, and urine albumin-to-creatinine ratio; review her current regimen and adherence barriers; and intensify treatment with cost-appropriate options while considering agents with cardiovascular/renal benefits when feasible. Secondary diagnosis—Hypertension: The 2025 AHA/ACC/partner guideline emphasizes accurate BP measurement, lifestyle therapy for all adults, and medication strategies to reduce cardiovascular risk; it supports lower BP targets for higher-risk groups, including many adults with diabetes (Jones et al., 2025). Integrated plan (visit-level): (1) Diagnostics: TSH/free T4; A1c; BMP/eGFR; urine albumin/creatinine; lipid panel; medication reconciliation; targeted screening (depression and sleep symptoms). (2) Communication: professional interpreter, teach- back, and simplified written instructions. (3) Treatment sequencing: initiate levothyroxine if confirmed; optimize antihypertensive therapy and diabetes regimen using guideline-concordant, affordable choices; and schedule follow-up consistent with caregiving demands. (4) Social supports: screen for cost/transportation barriers and connect to community resources (e.g., medication assistance programs). References American Diabetes Association. (2025). Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1).